Belatacept in Kidney Transplantation : What Are the True Benefits? A Systematic Review
Copyright © 2022 Lombardi and François..
The current gold standard to prevent allograft rejection for maintenance immunosuppression in kidney transplantation currently consists in glucocorticoids, an antiproliferative agent and a calcineurin inhibitor (CNI), with better outcome for tacrolimus than cyclosporin. Although, CNI drastically improved early graft survival, so far, CNI have failed to significantly improve long-term survival mainly because of nephrotoxicity. In addition, CNI carry several other side effects such as an increased risk for cardiovascular events and for diabetes mellitus. Therefore, seeking alternatives to CNI remains of paramount importance in kidney transplantation. Belatacept is a fusion protein composed of the human IgG1 Fc fragment linked to the modified extracellular domain of cytotoxic T lymphocyte-associated antigen 4. In kidney transplant recipients, pivotal phase III randomized studies suggested clinical benefits of belatacept as an initial maintenance regimen, as compared with cyclosporine, mainly on kidney function. Recently, a randomized study also suggested a clinical benefit on renal function of a conversion from a CNI-based to a belatacept-based maintenance regimen in patients. However, conversion from CNIs to belatacept is probably associated with an increased risk of biopsy-proven acute rejection and should prompt close clinical surveillance. On the other hand, other studies suggest a decrease in de novo humoral transplant immunization. Belatacept is probably associated with an increase in both risk and severity of some infectious diseases, including EBV-linked post-transplantation lymphoproliferative disorders, and with a decreased response to vaccines. Most studies on belatacept are observational, retrospective, and non-comparative. Consequently, high-quality data about the safety and efficacy profile of belatacept, as compared with the current gold standard for maintenance regimens (tacrolimus-based), is uncertain. Our review will therefore focus on the most recent published data aiming at evaluating the evidence-based or the "true" benefits and risks of belatacept-based regimens in kidney transplantation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Frontiers in medicine - 9(2022) vom: 15., Seite 942665 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lombardi, Yannis [VerfasserIn] |
---|
Links: |
---|
Themen: |
Avoidance (withdrawal) |
---|
Anmerkungen: |
Date Revised 02.08.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3389/fmed.2022.942665 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM344310825 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM344310825 | ||
003 | DE-627 | ||
005 | 20231226022455.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3389/fmed.2022.942665 |2 doi | |
028 | 5 | 2 | |a pubmed24n1147.xml |
035 | |a (DE-627)NLM344310825 | ||
035 | |a (NLM)35911396 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lombardi, Yannis |e verfasserin |4 aut | |
245 | 1 | 0 | |a Belatacept in Kidney Transplantation |b What Are the True Benefits? A Systematic Review |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 02.08.2022 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Copyright © 2022 Lombardi and François. | ||
520 | |a The current gold standard to prevent allograft rejection for maintenance immunosuppression in kidney transplantation currently consists in glucocorticoids, an antiproliferative agent and a calcineurin inhibitor (CNI), with better outcome for tacrolimus than cyclosporin. Although, CNI drastically improved early graft survival, so far, CNI have failed to significantly improve long-term survival mainly because of nephrotoxicity. In addition, CNI carry several other side effects such as an increased risk for cardiovascular events and for diabetes mellitus. Therefore, seeking alternatives to CNI remains of paramount importance in kidney transplantation. Belatacept is a fusion protein composed of the human IgG1 Fc fragment linked to the modified extracellular domain of cytotoxic T lymphocyte-associated antigen 4. In kidney transplant recipients, pivotal phase III randomized studies suggested clinical benefits of belatacept as an initial maintenance regimen, as compared with cyclosporine, mainly on kidney function. Recently, a randomized study also suggested a clinical benefit on renal function of a conversion from a CNI-based to a belatacept-based maintenance regimen in patients. However, conversion from CNIs to belatacept is probably associated with an increased risk of biopsy-proven acute rejection and should prompt close clinical surveillance. On the other hand, other studies suggest a decrease in de novo humoral transplant immunization. Belatacept is probably associated with an increase in both risk and severity of some infectious diseases, including EBV-linked post-transplantation lymphoproliferative disorders, and with a decreased response to vaccines. Most studies on belatacept are observational, retrospective, and non-comparative. Consequently, high-quality data about the safety and efficacy profile of belatacept, as compared with the current gold standard for maintenance regimens (tacrolimus-based), is uncertain. Our review will therefore focus on the most recent published data aiming at evaluating the evidence-based or the "true" benefits and risks of belatacept-based regimens in kidney transplantation | ||
650 | 4 | |a Systematic Review | |
650 | 4 | |a CNI toxicity | |
650 | 4 | |a avoidance (withdrawal) | |
650 | 4 | |a belatacept | |
650 | 4 | |a calcineurin avoidance | |
650 | 4 | |a costimulation blockade | |
650 | 4 | |a immunosuppressive therapy | |
650 | 4 | |a kidney transplantation | |
650 | 4 | |a maintenance therapy | |
700 | 1 | |a François, Hélène |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Frontiers in medicine |d 2014 |g 9(2022) vom: 15., Seite 942665 |w (DE-627)NLM245390847 |x 2296-858X |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2022 |g day:15 |g pages:942665 |
856 | 4 | 0 | |u http://dx.doi.org/10.3389/fmed.2022.942665 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2022 |b 15 |h 942665 |